↓ Skip to main content

Melhora no Consumo Máximo de Oxigênio e na Ventilação após Tratamento com Sacubitril-Valsartana

Overview of attention for article published in Arquivos Brasileiros de Cardiologia, October 2020
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
20 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Melhora no Consumo Máximo de Oxigênio e na Ventilação após Tratamento com Sacubitril-Valsartana
Published in
Arquivos Brasileiros de Cardiologia, October 2020
DOI 10.36660/abc.20190443
Pubmed ID
Authors

António Valentim Gonçalves, Tiago Pereira-da-Silva, Ana Galrinho, Pedro Rio, Rui Soares, Joana Feliciano, Rita Ilhão Moreira, Sofia Silva, Sandra Alves, Eunice Capilé, Rui Cruz Ferreira

Abstract

Sacubitril/valsartan had its prognosis benefit confirmed in the PARADIGM-HF trial. However, data on cardiopulmonary exercise testing (CPET) changes with sacubitril-valsartan therapy are scarce. This study aimed to compare CPET parameters before and after sacubitril-valsartan therapy. Prospective evaluation of chronic heart failure (HF) patients with left ventricular ejection fraction ≤40% despite optimized standard of care therapy, who started sacubitril-valsartan therapy, expecting no additional HF treatment. CPET data were gathered in the week before and 6 months after sacubitril-valsartan therapy. Statistical differences with a p-value <0.05 were considered significant. Out of 42 patients, 35 (83.3%) completed the 6-month follow-up, since 2 (4.8%) patients died and 5 (11.9%) discontinued treatment for adverse events. Mean age was 58.6±11.1 years. New York Heart Association class improved in 26 (74.3%) patients. Maximal oxygen uptake (VO2max) (14.4 vs. 18.3 ml/kg/min, p<0.001), VE/VCO2slope (36.7 vs. 31.1, p<0.001), and exercise duration (487.8 vs. 640.3 sec, p<0.001) also improved with sacubitril-valsartan. Benefit was maintained even with the 24/26 mg dose (13.5 vs. 19.2 ml/kg/min, p=0.018) of sacubitril-valsartan, as long as this was the highest tolerated dose. Sacubitril-valsartan therapy is associated with marked CPET improvement in VO2max, VE/VCO2slope, and exercise duration. (Arq Bras Cardiol. 2020; [online].ahead print, PP.0-0).

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 20 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 3 15%
Researcher 2 10%
Professor 1 5%
Student > Doctoral Student 1 5%
Student > Master 1 5%
Other 1 5%
Unknown 11 55%
Readers by discipline Count As %
Medicine and Dentistry 6 30%
Agricultural and Biological Sciences 1 5%
Unknown 13 65%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 December 2020.
All research outputs
#18,761,080
of 23,253,955 outputs
Outputs from Arquivos Brasileiros de Cardiologia
#740
of 1,098 outputs
Outputs of similar age
#312,500
of 415,972 outputs
Outputs of similar age from Arquivos Brasileiros de Cardiologia
#21
of 26 outputs
Altmetric has tracked 23,253,955 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,098 research outputs from this source. They receive a mean Attention Score of 3.3. This one is in the 18th percentile – i.e., 18% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 415,972 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.